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Many trials have explored the eﬃcacy of individual drugs and drug combinations to treat bancroftian ﬁlariasis. This narrative
review summarizes the current evidence for drug management of bancroftian ﬁlariasis. Diethylcarbamazine (DEC) remains the
prime antiﬁlarial agent with a well-established microﬁlaricidal and some macroﬁlaricidal eﬀects. Ivermectin (IVM) is highly
microﬁlaricidal but minimally macroﬁlaricidal. The role of albendazole (ALB) in treatment regimens is not well established
though the drug has a microﬁlaricidal eﬀect. The combination of DEC+ALB has a better long-term impact than IVM+ALB.
Recent trials have shown that doxycycline therapy against Wolbachia, an endosymbiotic bacterium of the parasite, is capable of
reducing microﬁlaria rates and adult worm activity. Followup studies on mass drug administration (MDA) are yet to show a
complete interruption of transmission, though the infection rates are reduced to a very low level.
1.Introduction
There are nine ﬁlarial nematodes causing disease in humans.
According to the location of the parasite and the pathogene-
sis, the disease can be classiﬁed as lymphatic, subcutaneous,
and serous cavity ﬁlariasis. Two ﬁlarial worms, namely,
Wuchereria bancrofti and Brugia malayi cause lymphatic
ﬁlariasis. The World Health Organization (WHO) considers
lymphatic ﬁlariasis to be a global health problem aﬀecting
approximately 120 million people in over 80 countries [1].
One-third of aﬀected individuals are from South Asia and
another one third is from Africa [1]. One sixth of the world
population is at risk of infection [1].
The adult W. bancrofti worms live within the human
lymphatic system. They have a long life span of 4–6 years.
Females are viviparous and release thousands of microﬁlaria
into the blood stream of the host after mating. These are
taken up by vector mosquitoes during feeding, and the
parasite undergoes several moults within the intermediate
host to become the L3 larva which is the infective stage.
During a feed, this larva enters the human blood stream and
migrates to the lymphatics where it moults to become an
a d u l tw o r m[ 2]. There is a range of clinical manifestations
in bancroftian ﬁlariasis with asymptomatic microﬁlaremics
being at one end of the spectrum. Symptomatic patients
may have acute (lymphangitis, lymphadenitis), chronic (ele-
phantiasis, lymphoedema, hydrocoele, chyluria), or atypical
(funiculitis, mastitis) manifestations [3]. Some may suﬀer
from tropical pulmonary eosinophilia (TPE) due to the
immunological hyperresponsiveness to the parasite [4].
The disease burden of lymphatic ﬁlariasis is signiﬁcant.
Chronic disease causes serious disﬁguration and incapacita-
tionofthepatientwithresultantstigmaandmarginalization.
It is a disease of the poor, and it signiﬁcantly aﬀects their
ability to earn an income. Many chronically ill patients are
nonproductive for the rest of their life and become a burden
tofamilyandsociety[1,5,6].Thisreviewfocusesonthedrug
treatment of lymphatic ﬁlariasis caused by W. bancrofti.
2.SearchStrategy andMethods
AM E D L I N Es e a r c hw a sc a r r i e do u tf o ra l la r t i c l e sw i t ht h e
key word “Wuchereria bancrofti” in any ﬁeld. The search was2 Journal of Tropical Medicine
restricted to articles published in English within the last 10
years (1999–2009), as they would contain more recent data.
There were 659 abstracts in the original search with these
restrictions. The software, Endnote X1.01 was used to ﬁlter
articles. Bibliographies of cited literature were also searched.
All abstracts were read through independently by the three
authors, and relevant ones were identiﬁed for review of the
full papers. Related papers were also included. Where the
full paper was not available online or as hard copies, we
contacted the authors and obtained the articles. Suitable data
was available in 73 papers.
Sources were screened for a well-described methodology,
accurate statistical analysis, and an adequate sample size
where relevant. Coding was done by three reviewers inde-
pendentlyblinded to each other. Interrevieweragreement for
ﬁnal review was 100%. Data sources included reviews pub-
lished in core clinical journals, cohort studies, interventional
studies, case control studies, cross-sectional analysis, and
epidemiological data. We reviewed 64 (87.6%) full papers
fromaselected73.Asummaryofthecitedliteratureisshown
in Tables 1 and 2.
One of the main issues that arose in evaluating the eﬃ-
cacy of therapies for bancroftian ﬁlariasis was the diﬀerences
in outcome measures of treatment used in diﬀerent trials.
Of these we identiﬁed the following key outcome measures:
(a) microﬁlaricidal eﬀect, (b) clearance of antigenaemia, (c)
macroﬁlaricidal eﬀect, and (d) prevention of clinical eﬀects
or complications of ﬁlariasis. The key pharmacological regi-
mens in the management of lymphatic ﬁlariasis are, diethyl-
carbamazine (DEC), albendazole (ALB), and ivermectin
(IVM) either used alone or in combination. We assessed
the eﬃcacy of each of these drugs or drug combinations
in achieving the above-mentioned outcome measures. The
value of these drugs in treatment of the individual and with
regards to mass treatment, were considered separately.
3. StandardTreatment with DEC
DEC has been used to treat lymphatic ﬁlariasis for over
50 years. Its mechanism of action is still not fully under-
stood. Earlier studies suggested that DEC had no direct
eﬀect on microﬁlaria as exposure to high concentrations
of DEC left them unharmed [7]. Later, evidence from in
vitro studies suggested that DEC blocks the cyclooxygenase
pathway in parasites and leads to death of microﬁlaria [8].
Peixoto et al. [9] have demonstrated that DEC induces
apoptosis in W. bancrofti microﬁlaria following exposure.
Due to this microﬁlaricidal activity of DEC, the blood is
cleared of microﬁlariae and the opportunity for mosquito
borne transmission to occur is reduced. Further, ﬁlaria-
associated haematuria and proteinuria are reversed. The
macroﬁlaricidal action of DEC is not intended to reverse
existing lymphatic damage but prevent further adult worm
associated lymphatic damage and dysfunction [10]. The
12-day regimen of 72mg/kg of DEC treatment remained
the standard treatment for bancroftian ﬁlariasis for many
years [11]. However, currently studies have indicated that
single-dose treatment with 6mg/kg DEC has comparable
macroﬁlaricidal and long term microﬁlaricidal eﬃcacy, and
this has been discussed. The 12-day course of DEC provides
more rapid short-term microﬁlarial suppression, but when
other factors are considered, including cost, convenience,
and patient compliance it seems feasible to recommend
single-dose treatment for individual patients with W. ban-
crofti infection. Single-dose treatment can be repeated every
6–12 months for persons who remain infected. However the
12-day regimen which reduces microﬁlarial density more
rapidly is recommended for patient with TPE or hematuria,
both of which are associated with microﬁlariae rather than
the adult worm [12]. DEC is not used in areas endemic for
onchocerciasis due to an increased side eﬀectproﬁle [13, 14].
4. Evidence from Clinical Trials on
Antiﬁlarial Agents
4.1. Single-Dose Treatment. Single dose treatment with DEC
isaseﬀectiveastheolderstandard12-daycourseofDEC,but
h a sf e w e ra d v e r s ee ﬀects and results in enhanced population
compliance and decreased delivery costs [15]. Single-dose
therapywithDEChasbeenassessedinseveraltrials(Table1).
In a prospective study in Egypt, a single dose of DEC
achievedamicroﬁlaria-clearancerateof69%(n = 20)after1
yearwhilethereductioninantigenaemiawaslesssatisfactory
(n = 86, 40.7%) [16]. A prospective trial in Sri Lanka
recorded a 74–80% reduction in microﬁlaria density (19–
28% microﬁlaria-clearance rate) with a single dose of DEC
6mg/Kg, 1 year after treatment [17]. However, the beneﬁt
of a single dose therapy may not be long lasting, as shown
in a 10-year followup study in Orissa, India [18]. In this
study of 44 patients, only 57% and 18% tested negative for
microﬁlaria and antigenaemia, respectively, at the end of the
followup period of 10 years after a single standard dose of
DEC. Similar evidence comes from Freedman et al. [19]w h o
demonstrated signiﬁcant levels of antigenaemia (clearance
rate of only 12%) at two years despite a more aggressive
treatment regimen with DEC (repeated dosing with 6mg/kg
for 12 days at 0, 6, 12, 18 months).
Pani et al. [20] demonstrated that either single dose
administration of DEC, ALB, or combination therapy were
not diﬀerent from each other with regard to microﬁlaria-
clearanceratesandreducingantigenaemia(P>. 05).Marked
reduction in mean geometric parasite density (P<. 05) as
well as antigenaemia optical density (P<. 01) was seen in all
groups at followup in 1 year.
Ivermectin is the third drug used in the treatment of
bancroftian ﬁlariasis. Regarding monotherapy with IVM,
Stolk et al. [21] demonstrated that single dose IVM alone
can achieve a high microﬁlaria kill rate and a worm
productivity loss at 1 year (96% and 82% on average, resp.).
In comparison, the rates for the DEC treated group were
very much lower (57% and 67%, resp.). Interestingly a
similar trial by Reddy et al. [22] (with high-dose IVM) who
followed up patients for two years suggests that both the
tolerability and eﬃcacy of the two drugs (IVM, DEC) were
not signiﬁcantly diﬀerent between gender, age, and weight
classesofpatientsattwoyears,althoughIVMshowedabetterJournal of Tropical Medicine 3
Table 1: Summary of clinical trials on drug treatment quoted in text.
Authors Year Study design Drug doses Outcome
Bockarie et al. 2007
Randomized
controlled clinical
trial
Single-dose DEC at 6mg/kg versus
DEC plus ALB 400mg single dose
No diﬀerence in microﬁlaricidal eﬀect but
combination therapy had more
macroﬁlaricidal eﬀect.
Fox et al. 2005
Randomized placebo-
controlled trial four
arms
(i) DEC 6mg/kg single dose
(ii) ALB 400mg single dose
(iii) Combination of both
(iv) Placebo
Combination therapy has a signiﬁcant
microﬁlaricidal eﬀect than either DEC or
ALB used alone.
Hussein et al. 2004 Prospective study two
arms
(i) DEC 6mg/kg and ALB 400mg
single dose
(ii) Same repeated daily for 7 days
Combination therapy reduced adult worm
activity by 90% after 1 year. No beneﬁt of
multiple dosing versus single dosing
beyond 3 months.
El Setouhy et al. 2004 Randomized clinical
trial two arms
(i) DEC 6mg/kg and ALB 400mg
single dose
(ii) Same repeated daily for 7 days
Greater and signiﬁcant microﬁlaricidal
eﬀects 1 year after treatment (eﬀect on
adult worms were similar) for multiple
dose combined therapy.
Pani et al. 2002
Double-blind hospital
based clinical trial
three arms
(i) DEC 6mg/kg single dose
(ii) ALB 400mg single dose
(iii) Combination of both
Single dose administration of DEC, ALB,
or combination therapy were not diﬀerent
from each other with regard to
microﬁlaria-clearance rates and reducing
antigenaemia.
Dreyer et al. 2006
Randomized
controlled clinical
trial two arms
(i) DEC 6mg/kg single dose
(ii) DEC 6mg/kg + ALB 400mg single
dose
Signiﬁcant reduction in macroﬁlaricidal
eﬀect in the combined regime compared to
DEC alone (P = .016) with no additional
eﬀect on microﬁlaria rates.
Ramzy et al. 2002 Prospective study Single-dose DEC 6mg/kg
DEC single dose therapy achieved a
microﬁlaria-clearance rate of 69% in one
year with a 40.7% reduction in
antigenaemia.
Weerasooriya et al. 1998 Prospective study Single-dose DEC 6mg/kg
A reduction in microﬁlaria density by
74–80% and a 19–28% microﬁlaria
clearance rate at 1 year after treatment.
Weerasooriya et al. 2002 Prospective study A 12-day course of DEC 6mg/kg
Microﬁlaria clearance achieved in 78% of
infected people. However, 76.1% of them
remained positive for the Og4C3 antigen at
end of 17 months.
Beuria et al. 2002 Prospective study DEC 6mg/kg for 12 days
Only 57% and 18% tested negative for
microﬁlaria and antigenaemia, respectively
at the end of the followup period of 10
years.
Freedman et al. 2001 Prospective study DEC 6mg/kg for 12 days at 0,6,12,18
months
Only 12% clearance rate of antigenaemia
at the end of a followup period of 2 years.
Beach et al. 1999
Randomized
placebo-controlled
clinical trial four arms
(i) IVM 200–400μg/kg single dose
(ii) ALB 400mg single dose
(iii) Combination of both
(iv) Placebo
Combined therapy with ALB and IVM
reduces microﬁlaraemia more than
placebo or individual drugs
Richards et al. 2005 Prospective
entomological survey
The combination of ALB and IVM appears
to be superior to IVM alone for reducing
the frequency of W. bancrofti infection in
mosquitoes.
Dunyo et al. 2000
Double-blind
placebo-controlled
ﬁeld trial two arms
(i) IVM 150–200μg/kg single dose
(ii) IVM 150–200μg/kg + ALB 400mg
single dose
Both IVM and combination treatment
appeared eﬀective for control of W.
bancrofti infections, but the diﬀerence in
eﬃcacy between the 2 treatments after 12
months appeared to be minimal.4 Journal of Tropical Medicine
Table 1: Continued.
Authors Year Study design Drug doses Outcome
Ismail et al. 1996 Double-blind clinical
trial two arms
(i) 400μg/kg of IVM 12 fortnightly
doses
(ii) 10mg/kg of DEC 12 fortnightly
doses
IVM has higher microﬁlarial (mf)
clearance, and DEC has higher
antigenaemia (ag) clearance. Both
therapies had residual mf and ag levels
comparable with each other following 1
and 3 months of dosing, respectively.
Ismail et al. 1998 Blinded four-arm
clinical trial
(i) ALB 600mg single dose
(ii) ALB 600mg + IVM 400μg/kg
(iii) ALB 600mg + DEC 6mg/kg
(iv) IVM 400μg/kg + DEC 6mg/kg
All 4 treatments signiﬁcantly reduced mf
counts, but ALB/IVM was the most
eﬀective regimen for clearing mf from
night blood. All 4 treatments had
signiﬁcant activity against adult W.
bancrofti with DEC+ALB having the
greatest eﬀect (Followup:15 months).
Ismail et al. 2001 Blinded three-arm
clinical trial
(i) ALB 400mg + IVM 200μg/kg
(ii) ALB 400mg + DEC 6mg/kg
(iii) ALB 600mg + IVM 400μg/kg
All 3 treatments signiﬁcantly reduced mf
counts, with the ALB-DEC-treated group
showing the lowest mf levels at 18 and 24
months after-treatment. All 3 treatments
had signiﬁcant activity against adult W.
bancrofti; ALB-DEC combination had the
greatest activity.
Makunde et al. 2003
Crossover,
double-blind design
two groups
For group with coinfection with W.
bancrofti and O. volvulus-single dose of
IVM 150μg/kg + 400mg ALB versus
placebo. Treatment was crossed over
after 5 days of initial dosing
For group with only W. bancrofti
infection-Single dose of ALB 400mg
versus ALB+IVM 150μg/kg
There was no signiﬁcant diﬀerence in the
reduction of microﬁlaraemia following
treatment with ALB and IVM in groups
with single or coinfection. IVM plus ALB
is a safe and tolerable treatment for
coinfection of bancroftian ﬁlariasis and
onchocerciasis.
Stolk et al. 2005 Prospective two-arm
study two arms
(i) 400μg/kg IVM single dose
(ii) 6mg/kg DEC single dose
IVM on average killed 96% of Mf and
reduced Mf production by 82%. DEC
killed 57% of Mf and reduced Mf
production by 67%.
Reddy et al. 2000 Double-blind
two-arm clinical trial
(i) 400μg/kg IVM single dose
(ii) 6mg/kg DEC single dose
Tolerability and eﬃcacy of the two drugs
(IVM, DEC) were not signiﬁcantly
diﬀerent between gender, age, and weight
classes of patients at two years.
Debra et al. 2006
Double-blind
placebo-controlled
trial
Doxycycline 200mg/d for 6 weeks
followed by IVM 150μg/kg + 400mg
ALB single dose 4 months later
Wolbachia load, microﬁlaraemia,
antigenaemia, and frequency of ﬁlarial
dance sign were signiﬁcantly reduced in
microﬁlaraemic patients up to 24 months
in the doxycycline group compared to the
placebo group.
Debra et al. 2009
Double-blind
placebo-controlled
trial
Doxycycline 200mg/d for 6 weeks
followed by IVM 150μg/kg + 400mg
ALB single dose 4 months later
Six-week regimen of doxycycline treatment
showed improvement of clinical features of
hydrocoele patients with active infection.
Taylor et al. 2005
Double-blind
placebo-controlled
randomized trial
Doxycycline 200mg/d for 8 weeks
An 8-week course of doxycycline is a safe
and well-tolerated treatment for lymphatic
ﬁlariasis with signiﬁcant activity against
adult worms and microﬁlaraemia.
responseatoneyear.IVMisavoidedinareasendemicforLoa
loa [23, 24].
4.2. Single Dose versus Combination Therapy. There
are several studies comparing single drug therapy with
combination therapy. Dreyer et al. [25] report a signiﬁcant
reduction in macroﬁlaricidal eﬀect in the combined regime
of DEC and ALB compared to DEC alone (P = .016) with
no additional eﬀect on microﬁlaria reduction rates. In a
large randomized controlled clinical trial, Bockarie et al.Journal of Tropical Medicine 5
[26] demonstrated that single dose DEC (6mg/Kg of body
weight) has no superiority over combination therapy (DEC
with ALB 400mg single dose) in reducing microﬁlaria
rates over a followup period of 2 years. Nonetheless,
combination therapy had a signiﬁcant macroﬁlaricidal
eﬀect (P<. 003) compared to DEC alone at the end
of followup (the antigen Og4C3 prevalence was used to
measure adult worm activity). Fox et al. [27], in a large scale
(n = 990) randomized placebo-controlled trial, showed
that combination therapy has a signiﬁcant microﬁlaricidal
eﬀect compared to DEC or ALB used alone (P<. 03). In
as m a l l e rp r o s p e c t i v es t u d y ,H u s s e i ne ta l .[ 28]( n = 58)
demonstrated that ultrasonographic evidence of adult worm
nests showed a 90% reduction after 1 year from start of
combination therapy with DEC+ALB. It was also shown that
single dose therapy versus multiple doses (over 7 days) had
no additional beneﬁt in this regard. Conﬂicting evidence
comes from El Setouhy et al. [29] who report signiﬁcantly
greater microﬁlaricidal and macroﬁlaricidal eﬀects at 1 year
for multiple doses of combined therapy with ALB+DEC.
IVM is usually administered in combination with ALB.
Two studies have shown that the combination is more
eﬀective in killing microﬁlaria in humans and reducing
infection rates in the vector than individual drugs or placebo
[30, 31]. There is some speculation that IVM aﬀects the
reproductive capacity of female worms [32]. Five clinical
trialsinSriLanka[33,34],Ghana[35,36],andTanzania[37]
with a followup for 1-2 years have demonstrated the eﬃcacy
of ALB and IVM combination on microﬁlaria clearance.
Two studies [33, 34] had an arm treated with high-dose
IVM (400μg/Kg) and ALB (Table 1). The Sri Lankan trials
also compared the eﬃcacy of IVM and ALB with DEC and
ALB. Almost all regimens with IVM demonstrated a rapid
kill rate of microﬁlaria with higher doses showing a greater
reduction in microﬁlaria rates. A subsequent mathematical-
model-based analysis based on these 5 trials has shown that
thereductionofmicroﬁlariawithDECandALBisslowerbut
long lasting [38]. While constructing the model, the authors
have tried to assess the trends in microﬁlaria densities in
severaltrialsafterstartingtreatmentwithdiﬀerentantiﬁlarial
drug combinations. Since the study populations were from
endemic areas, it was assumed that before the start of
treatment the microﬁlarial densities were at an equilibrium
(production matched by elimination) and the eﬀect of drugs
were described in two terms; microﬁlaria loss (fraction of
microﬁlaria killed) and worm productivity loss (fraction of
microﬁlaria permanently rendered incapable of reproduc-
ing). As the maximum followup was 2 years in the studies
entered into the model, new infections were thought not to
aﬀect the equilibrium as they would not yield microﬁlaria
during this period due to the long premature period of
the worm. By using this model authors have also tried to
estimate how the microﬁlarial densities would change in the
posttreatment period. From observed data, DEC- and ALB-
based trials had an almost 100% worm productivity loss at
both high and low doses of ALB while only the high-dose
combinations ofIVM andALBrecordedsimilarresults.Even
after allowing for acquisition of new infections, the eﬃcacy
estimates did not vary between the trial arms. Ismail et al.
[33] recommend that ALB and DEC are a better option for
mass chemotherapy for endemic populations, based on the
high rates of microﬁlarial clearance.
Bockarie et al. [39–41], in a prospective study, recruited
nearly 2500 people to receive four rounds of annual treat-
ment in Papua New Guinea. They were randomly assigned to
twotreatmentgroupstoreceiveeitherDECandIVMorDEC
alone.Afterfourroundsoftreatment(77%–86%compliance
rate), microﬁlaria positive infections were reduced by 86–
98%. Chronic manifestations such as lymphoedema and
hydrocoele were also signiﬁcantly reduced in the population
(P = .04, <.001, resp.). There was no diﬀerence in the
two drug regimens with regard to eﬃcacy. However, the
combination of IVM and DEC rapidly reduced microﬁlaria
positivity, especially in high-transmission areas. Still, at the
end of the four years, the odds of microﬁlaria transmission
were the same for both regimens.
A double-blind clinical trial on a head-to-head com-
parison of high-dose IVM and DEC showed that IVM
has a higher microﬁlarial clearance and DEC has a higher
antigenaemia clearance [42]. Both therapies had residual
microﬁlaria and Ag levels comparable with each other
following 1 and 3 months of dosing, respectively.
4.3. Treating the Masses: Evidence from Mass Treatment
Programmes. In 1997, WHO drew the blueprint to eliminate
lymphatic ﬁlariasis by 2020 [1]. Mass drug administration
(MDA) in endemic areas/countries was considered to be
more cost eﬀective than detecting and treating infected
individuals. The low side eﬀect proﬁle of drugs and the
pledge by two pharmaceutical companies to provide them
free of charge, as long as necessary, made MDA a good
elimination strategy. Currently, an estimated 754 million
people in 81 countries are targeted for MDA and 546 million
are already receiving it. Sixty-one countries have completed
mappingofendemicareas,andinanother16itisinprogress.
ChinaandSouthKoreahavealreadydeclaredtheelimination
of lymphatic ﬁlariasis as a public health priority [43]. The
use of MDA in ﬁlariasis gives the unique opportunity to
see how the results of smaller clinical trials are valid when
the drugs are administered to masses of general population.
Currently there are three regimens approved for MDA,
namely,DECwithALB,IVMwithALB,andDEC-medicated
salt [43].
In Burkina Faso, MDA with IVM alone (for onchocer-
ciasis) has shown an indirect beneﬁt by lowering W. ban-
crofti microﬁlaria rates. Kyelem et al. [44] reported that,
in comparison to nonendemic and, therefore, nontreated
communities, the treated communities had signiﬁcantly
lower microﬁlaria rates after six rounds of annual treat-
ment. However, the rates of hydroceles and lymphoedema
did not diﬀer in the two communities. Furthermore, an
entomological survey by Richards et al. [45] did not ﬁnd
signiﬁcantly lower rates of infection in mosquitoes with W.
bancrofti larvae in treated and untreated communities with
IVM in Nigeria (MDA for onchocerciasis). All communities
had good compliance with MDA, but only two rounds of
treatment were completed in three of the ﬁve communities6 Journal of Tropical Medicine
Table 2: Summary of followup studies on cohorts receiving mass drug administration.
Author Year
published Design Drug regimen Followup Conclusions
Bockarie et al.,
Papua New
Guinea
2002
Prospective
controlled
randomized
clinical trial
(i) DEC 6mg/kg single dose
(ii) DEC 6mg/kg + IVM
single dose
5 years
Microﬁlaria positive infections were
reduced by 86%–98%. Chronic
manifestations such as lymphoedema and
hydrocoele were also signiﬁcantly
reduced in the population. No diﬀerence
in two regimens at end of followup.
Kyelem et al.,
Burkina faso 2003 Prospective
two-arm study
Communities receiving
IVM 150μg/kg annually
compared with
communities not receiving
MDA
6 years
Long-term IVM (given for
onchocerciasis) signiﬁcantly reduced W.
bancrofti and M. perstans
microﬁlaraemia.
Richards et al.,
Nigeria 2005
Cross-sectional
entomological
survey
Communities receiving
IVM 150μg/kg annually
2-3 annual
rounds of
chemotherapy
completed
Annual therapy with IVM for
onchocerciasis has not interrupted
transmission of Wuchereria bancrofti.
Ramaiah et al., 2007
Community-based
followup study
with two arms
DEC 6mg/kg, single dose
annual therapy versus IVM
400μg/kg single dose
annual therapy
10 years
DEC had the potential to interrupt
transmission while the capability of IVM
to do so was less.
Liang et al., 2008 Followup study DEC + ALB standard
dosing 6 years
The antigenaemia prevalence dropped
from 11.5% in 2001 to 0.95% in 2006
(P<. 0001).
Mataika et al.,
Fiji 1995 Followup study Annual single dosing of
DEC 6mg/kg 5 years
MDA with DEC alone led to a statistically
signiﬁcant reduction in microﬁlaria rates
irrespective of the pretreatment mf rates.
Freeman et al.,
Haiti 2001 community-based
trial DEC medicated salt 1 year
DEC and Iodine fortiﬁed salt lowered the
prevalence and intensity of
microﬁlaraemia by 95%. Impact on adult
worms was less.
Meyrowitsch et
al., Tanzania 1996 community-based
trial
Comparison of four
strategies of community
treatment with DEC
6mg/kg
(i) 12 day regimen
(ii) Semiannual single dose
treatment
(iii) Monthly low dose
regimen
(iv) DEC medicated salt
2 years
Strategies III and IV were equally
eﬀective, and superior in clearing
microﬁlaraemias and in reducing mf
geometric mean intensities compared to
strategies I and II.
Meyrowitsch et
al., Tanzania 2004 community-based
trial Followup of above-study 10 years Microﬁlaria rates were reaching
pretreatment values in all communities.
Fan et al., China 1990 Community-based
trial DEC medicated salt 12 years
Microﬁlaria rates and infection rates were
reduced from 9.6% to 0.3% and 9.1% to
0.8%, respectively.
Liu et al., China 1992 Community-based
trial DEC medicated salt 4 years
Microﬁlaria rates dropped from a range
of 1.56–11.81% to 0.05% in the
communities studied.
Sunish et al.,
India 2002
Community-based
trial with three
arms
Group A: MDA with
annual single dose of IVM
400μg/kg + DEC 6mg/kg
G r o u pB :M D Aw i t hv e c t o r
control
Group C-Placebo
3-4 years
The improvement with MDA was
sustained in the second group while
resurgence occurred in the ﬁrst group.Journal of Tropical Medicine 7
Table 2: Continued.
Author Year
published Design Drug regimen Followup Conclusions
Simonsen et al.,
Eastern Africa 2004
Community-based
trial in
high-endemicity
and
low-endemicity
communities
Semiannual treatment with
DEC 6mg/kg 1 year
Transmission rates dropped only in high
endemicity communities, but it cannot
be entirely attributed to MDA.
Esterre et al., 2001 Community-based
followup study
Semiannual treatment with
DEC 6mg/kg for more
than 30 years
34 years Microﬁlaria and antigenaemia rates were
very low but not zero.
studied. A community-based trial on head to head compar-
ison on the eﬃcacy of DEC (6mg/kg, single dose) and IVM
(400μg/kg, single dose) in South India has shown that after
10 years of annual MDA, DEC had the potential to interrupt
the transmission of ﬁlariasis while IVM was less able to do so
[46].
ALB and DEC are used as a combination for MDA in
manynononchocerciasis-endemicpopulations,andhasbeen
proven to be eﬀective. After 6 years of MDA in American
Samoa, the antigenaemia prevalence dropped from 11.5%
in 2001 to 0.95% in 2006 (P<. 0001) with this regimen
[47]. MDA for ﬁve years with DEC alone in Fiji has also
shown a statistically signiﬁcant reduction in microﬁlaria
rates irrespective of the pretreatment microﬁlaria rates [48].
4.4. The Role of DEC-Fortiﬁed Salt. DEC-medicated cooking
salt has been used to facilitate mass treatment and has
proved to be very eﬀective and safe. DEC fortiﬁed salt
has been recommended mainly for control programmes
chieﬂybecauseofitsabilitytoclearmicroﬁlaraemiaswithout
causing adverse reactions. It is anticipated that this approach
would ensure compliance. The lack of adverse eﬀects is
due to the very slow clearance of parasitaemia compared
with that achieved with tablets. DEC medicated salt plays a
major role in the Chinese ﬁlariasis control programme and
proved successful in more limited trials in India, Brazil, and
Tanzania [49–52]. It has been shown that DEC salt is more
eﬀective than single dose DEC in reducing the prevalence of
microﬁlaraemia. DEC fortiﬁed salt may be useful in areas
where the mobilisation of the population for annual drug
distribution is diﬃcult. Common salt medicated with 1–
3g of DEC per kg is used for atleast 6–12 months. It is
well tolerated and safe to use in pregnancy. It is colourless,
odourless, thermostable, and tastes the same as ordinary
cooking salts. The macroﬁlaricidal eﬀect of very low-dose
DEC as used in the DEC medicated salt is not sure. Low
dose DEC in salt minimizes or avoids completely the known
side eﬀects of treatment, including both acute pharmaco-
logic eﬀects of high doses and Mazzotti-like inﬂammatory
reactions (probably due to dying microﬁlariae) induced by
moderate and high doses [53].
Several pilot studies have been conducted using salt
fortiﬁed with DEC in endemic communities in India,
Tanzania,andBrazil.Allofthemhavedemonstratedeﬀective
microﬁlariakillrates[49,51,52,54–56].Alargecommunity-
based trial in Haiti, over a period of 1 year has shown
that DEC- and Iodine-fortiﬁed salt lowered the prevalence
and intensity of microﬁlaraemia by 95% [57]. However, the
impact on adult worms was less (60% reduction in Og4C3
antigenaemia and a nonsigniﬁcant reduction in motility of
worm nests detected by ultrasound).
5. Resurgence after MDA: Is Eradication
Possible?
WHO aims to achieve cessation of transmission of infection
after 4–6 rounds of therapy yearly (which corresponds to the
fecundity of the adult worms) provided the compliance is
good. However, initial small-scale trials failed to completely
clear microﬁlaria rates with either combination of drugs,
though the ALB+DEC combination had a lasting eﬀect. The
followup studies after several MDA rounds conﬁrm this.
Meyrowitsch et al. [58]r e p o r tt h a ta f t e r1 0y e a r so fM D A
with DEC (given in three regimens) the microﬁlaria levels
were reaching the pretreatment value in all communities.
Many of the recurrences were in previously microﬁlaria
positiveindividualsindicatingthepossibilityofreproduction
from surviving female adults. A three-arm community-
based trial in India assessed the impact of two rounds
of annual MDA after 3 years since the last dosing. The
improvement with MDA was sustained when therapy was
combined with vector control [59, 60]. The importance
of vector control and understanding of local transmission
dynamics are also underscored by Simonsen et al. [61], who
have shown that after two rounds of MDA, mosquitoes
carrying infective larvae were not reduced, though mf rates
in the community were signiﬁcantly less. The most suitable
cohort to study the impact of long-term MDA is the Maupiti
cohort of French Polynesia where semiannual MDA has been
combined with vector control since 1955. Two surveys in
1985 and 1989 showed a 0% microﬁlaria rate which gave
hope that eradication was complete. Nonetheless, Esterre et
al. [62] in two repeated cross-sectional analyses in 1997 and
1999 have shown residual microﬁlaraemia and antigenaemia
(0.4% and 4.6%, resp.) with a 1.4% infectivity rate in vector
population. There are several plausible explanations for this8 Journal of Tropical Medicine
observation: eﬃciency of the vector, resistance to DEC, and
prolonged longevity of adult worms. These ﬁndings cast
doubt on the possibility of a complete “eradication” of
ﬁlariasis with MDA.
In this background, Micheal et al. [63, 64] suggest that
plans to control lymphatic ﬁlariasis should be more prag-
matic, ﬂexible, economically sensitive, and sequential. They
suggest that the ﬁrst target in an elimination programme
should be to achieve an infection rate at which chronic
manifestations of infection (causing more productivity loss
and DALYs) become negligible despite ongoing infection.
Using a mathematical model based on available data it
is suggested that a microﬁlaria rate of 3.55% at a blood
sampling volume of 1 ml will achieve this. This target is both
achievable and sustainable with current MDA regimens.
6.Resistance toDrugs
One factor linked to resurgence of infection following MDA
is the resistance to drugs. It is impossible to assess the
resistance to DEC as its mechanism of action is still obscure.
However, resistance to IVM and ALB has been reported
in nematodes in veterinary practice. In 2004, resistance to
IVM was reported in the human parasite Oncocerca volvulus
[65]. There are yet no conﬁrmed reports of resistance in W.
bancrofti for IVM.
The main cause for concern, however, is resistance to
Benzimidazoles (BZ), namely, ALB. The resistance to BZs
(ALB, Mebendazole) is seen in many nematode parasites
due to single nucleotide polymorphisms (SNP) [66]. Two
SNPs substituting tyrosine for phenylalanine of the β tubulin
protein of nematodes confer resistance to ALB in veterinary
practice. Schwab et al. [67, 68] has demonstrated that
similar SNPs exist in W. bancrofti in untreated populations,
and such mutations are selected for after mass treatment.
The impact of this may not be felt immediately in the
population as microﬁlarial rates drop rapidly with combined
chemotherapy. Still, if resurgence occurs in future, resistant
genotypes with a selection advantage may predominate in
the parasite population making ALB resistance a signiﬁcant
problem. However, as some authors point out, the real
problem is not related to W. bancrofti at all it is the possibility
of other intestinal nematodes developing resistance to BZs
due to large scale exposure to ALB during MDA that could
pose a serious threat to health of children and adults in
endemic areas [69].
7. The Place for Targeting Wolbachia with
DoxycyclineinTreatmentRegimens
Wolbachia is an intracellular symbiotic bacterium of ﬁlarial
parasites. It plays an essential role in larval moulting,
adult worm survival, and female worm fertility. Killing the
bacterium with doxycycline has shown promise in many
studies by reducing adult worm activity [70, 71]. Though
doxycycline therapy has been experimented with for treating
infections with other ﬁlarial worms, the ﬁrst trial with regard
to W. Bancrofti was conducted in 2005 by Taylor et al. [72]
after 8 weeks of doxycycline 200mg/d, microﬁlaraemia was
almost eliminated (P<. 001), antigenaemia was halved
(P = .015), and ultrasonographically demonstrated adult
worm activity was signiﬁcantly less (P<. 0001) in the
treatment group versus placebo group (after 14 months of
followup). There were no serious side eﬀects with treatment.
Subsequent studies with shorter courses of doxycycline (6,
and 4 weeks, resp.) have shown a similar eﬀect. In these
studiesantibacterialtherapywasfollowedupwithIVM+ALB
combined therapy [73, 74]. However, a 3-week course of the
drug failed to show an adequate macroﬁlaricidal eﬀect [75].
In addition to killing the endosymbionts and reducing
the ﬁlarial worm load, doxycycline also improves clinical
manifestations of ﬁlariasis. The levels of vascular endothelial
growth factor C (VEGF-C) and soluble vascular endothelial
growth factor receptor-3 [(s)VEGFR-3], which has been
shown to be important in pathogenesis of ﬁlariasis in animal
models, were lowered in test subjects following doxycycline
therapy [76]. The macroﬁlaricidal eﬀect of doxycycline is
slow compared to DEC, and the side eﬀects seen after
DEC treatment (abscesses, etc.) are not seen. Addition of
doxycycline to treatment regimens will have a beneﬁcial
eﬀect especially in Onchocercaria endemic areas where DEC
is contraindicated. IVM used in these areas have no or
minimum macroﬁlaricidal eﬀect.
8. Limitations
This review was limited to articles published in English
within 1999–2009 time period. While attempts were made to
search related literature as well, it is possible that important
studies published in other languages and outside the search
limits were missed.
9. Conclusions
WHO has outlined two objectives for its campaign of MDA:
to interrupt transmission and to reduce morbidity of disease
[1]. The best combination of drugs for an MDA programme
was still not clariﬁed by the time the programmes were
launched in endemic areas. Clearly, one of the main dif-
ﬁculties in determining the eﬃcacy of individual drugs is
that diﬀerent endpoints have been used in diﬀerent trials
(microﬁlaria-clearance rates, antigenaemia-clearance rates
etc.), and correlating eﬃcacy based on these endpoints and
actual clinical eﬃcacy is diﬃcult. As individual drugs, IVM
reduced the microﬁlaria rates rapidly, but DEC had more
macroﬁlaricidal eﬀects with a higher clearance of antige-
naemia.Theonlyavailablelarge-scalecommunity-basedtrial
toevaluateIVMversusDEC,showedthatthelatterwasmore
eﬀective in interrupting transmission [46]. The evidence for
beneﬁts of combination therapy is also conﬂicting but many
studies favour it. Only two studies quoted above show no
diﬀerence between single and combination therapy while
Dreyer et al. [25] actually report a loss in macroﬁlaricidal
eﬀect of DEC when given in combination. However, this
study uses ultrasound evidence to assess outcome rather
than the antigen clearance. It may be diﬃcult to correlateJournal of Tropical Medicine 9
antigenaemia to macroﬁlaricidal eﬀects as shown by a large
scale study in Sri Lanka. After a 12-day course of DEC, 78%
showed microﬁlaria clearance. However, of 76% of those
“cured” parasitologically were still positive for the Og4C3
antigen at 17 months [77]. The ALB+DEC regimen was
considered a better option for nononchocercaria endemic
areas than the ALB+IVM regimen. Nonetheless, large-scale
randomized clinical trials are not available to formulate
evidence-based guidelines for chemotherapy, and currently
only recommendations can be made in treating bancroftian
ﬁlariasis based on available evidence.
Despite 50 years of research into ﬁlariasis control, still
many questions remain unanswered. These include basic
issues like mechanism of action of DEC, best combination
of drugs for elimination strategies, and evidence-based
recommendations to treat lymphatic ﬁlariasis. Diﬀerences
in the end-points of treatment studied add confusion to
the beneﬁts of the diﬀerent drugs and drug combinations.
Much of the recommendations for therapy are based on
microﬁlaraemia and antigenaemic clearance; evidence of
reduction of clinical manifestations has not been studied
adequately in either large-scale population surveys or clinical
studies.Theneedtoidentifyclearendpointsinfutureclinical
trials and population surveys cannot be overemphasised.
The policies of MDA also need to be reviewed, and, as
community-based studies have shown, despite intensive
therapy, that infection rates have not been reduced to
zero. It is important to combine vector control with MDA
and develop elimination strategies that are ﬂexible and
achievable in local context. Perhaps it is more important
to target an infection rate that reduces the impact of
lymphatic ﬁlariasis as a public health problem rather than
aim towards total eradication, as eventually what matters
is that the clinical manifestations of lymphatic ﬁlariasis are
prevented.
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